Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Exome sequencing of p53/Mps1 murine tumours

ABSTRACT: Exome sequencing of p53/Mps1 murine tumours

PROVIDER: PRJEB13719 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1370960_1.fastq.gz	Fastqsanger.gz
	ERR1370960_2.fastq.gz	Fastqsanger.gz
	ERR1370961_1.fastq.gz	Fastqsanger.gz
	ERR1370961_2.fastq.gz	Fastqsanger.gz
	ERR1370962_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Exome sequencing of p53/Mps1 murine tumours

Project description:To investigate karyotype heterogeneity in tumours exhibiting chromosomal instability, we sequenced exomes of Mps1f/f; p53f/f; Lck-Cre+ and Mps1f/f; p53f/+; Lck-Cre+ mice,

2016-04-27 | E-MTAB-4181 | biostudies-arrayexpress

Transcriptional Profiling of Mouse Tumours

Project description:Murine small intestinal and colonic tumours with mutations in combinations of Kras, P53, Notch1, Apc and Braf.

2023-04-05 | GSE218776 | GEO

Transcriptional profiling of lung tumour cell lines with distinct p53 mutations in the absence or presence of WT p53

Project description:Microarray expression data generated to determine the impact of defined p53 mutations on lung cancer cell phenotypes, and on the tumour supressive responses induced by WT p53 restoration. In murine models of lung cancer, the therapeutic benefit of WT p53 restoration has been demonstrated in p53-deficient tumours (Juntilla et al, 2010; Feldser et al, 2010). However, it remains unknown if the restoration of WT p53 function is beneficial in p53 mutant tumours. Thus, to determine the impact of p53-targeted therapy in mutant p53 lung cancer, we analysed cells from murine lung tumours of distinct p53 genotypes. Utilising the well characterised p53-ER allele (Christophorou et al, 2005; Martins et al, 2006; Juntilla et al, 2010) we carried out transcriptional profiling of KrasG12D/+ cell lines isolated from advanced lung tumours with defined p53 status: p53Fx/ER (null), p53R270H/ER and p53R172H/ER in the absence (p53 WT OFF) or presence (p53 WT ON) of 4-hydroxytamoxifen (4-OHT). The temporal specificity of p53-ER restoration allowed us to utilised two timepoints to determine both the immediate (2hr) and sustained (8hr) impact of WT p53 function.

2017-08-09 | GSE94758 | GEO

Genome wide analysis of tumours in individuals with p53-germline mutations

2012-01-19 | GSE34323 | GEO

Transcriptomic profiling and analyses of murine prostate tumours

Project description:Transcriptomic profiling and analyses of murine prostate tumours

| PRJNA561182 | ENA

Whole exome sequencing of NT2.5 and NT2.5-LM cell lines

Project description:NT2.5-LM is a cell line derived from the parental NT2.5 cell line that provides a more proliferative and metastatic murine model of breast cancer. We used whole exome sequencing to examine mutational differences.

2024-06-30 | GSE261253 | GEO

Genomic landscape of carcinogen induced mouse skin squamous cell carcinoma: whole-exome sequencing

Project description:Whole-exome sequencing of induced murine squamous cell carcinoma. 26 samples are included.

2014-09-11 | E-MTAB-2887 | biostudies-arrayexpress

Genome wide analysis of tumours in individuals with p53-germline mutations

Project description:Copy number analysis of Affymetrix GW6.0 SNP/CNV arrays was performed for 7 tumours (4 adrenocortical carcinomas, 2 rhabdomyosarcoma and 1 extra-renal rhabdoid tumour) derived from individuals with germline p53-mutations. Affymetrix CNV/SNP arrays were performed according to the manufacturer's directions on DNA extracted from fresh frozen tumour samples

2012-01-19 | E-GEOD-34323 | biostudies-arrayexpress

In situ depletion of Nuak1 in murine colon tumours

Project description:In situ depletion of Nuak1 in murine colon tumours

| PRJEB23698 | ENA

RNA-Seq of KRAS-regulated genes in a murine cell line and lung tumours

Project description:A murine lung cancer cell line, and derived lung tumours, were treated with a KRASG12C inhibitor for different time points

2022-08-24 | GSE183548 | GEO